Results from a new clinical study which included 2,855 patients with high cholesterol showed that VYTORIN(R) (ezetimibe/simvastatin) was significantly more effective than Crestor(R) (rosuvastatin) in reducing LDL "bad" cholesterol across all study dose comparisons, 52-61 percent for VYTORIN 10/20 mg to 10/80 mg and 46-57 percent for Crestor 10 mg to 40 mg. In addition, both VYTORIN and Crestor raised HDL "good" cholesterol by 8 percent, averaged across all doses studied. The primary endpoint of the study was LDL cholesterol reduction from baseline averaged across all doses. Key secondary endpoints included LDL cholesterol reductions from baseline at each dose comparison. With the results of this study, VYTORIN now has been shown in clinical studies to provide greater LDL cholesterol lowering efficacy versus Zocor (simvastatin), Lipitor (atorvastatin) and Crestor (rosuvastatin) at all study dose comparisons.

In a post-hoc subgroup analysis of 715 high risk patients included in the study, the results revealed that VYTORIN, as a result of greater LDL cholesterol reduction, helped significantly more high-risk patients achieve an LDL cholesterol of less than 70 mg/dL and less than 100 mg/dL compared to patients taking Crestor (50 percent vs. 29 percent; p About the study

This double-blind, six-week, parallel-group study included 2,855 patients. Patients were randomized equally to one of six treatment groups.

VYTORIN provided significantly greater LDL cholesterol reduction, compared to Crestor, when averaged across all dose comparisons (56 percent vs. 52 percent; p